KRAS and cancer: KRASG12C inhibitors not only affect the survival of cancer cells but also can mediate immunomodulatory effects by reversing KRAS-driven immunosuppressive mechanisms and generate a TME that is more favorable for an antitumor immune response (8, 19, 21).